Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the single-dose relative bioavailability of Mylan
Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg
bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed
conditions.